Thibault Schulthess

Associate

Paris + 33.1.56.59.46.01

Connect:

Share

Thibault Schulthess regularly advises French and foreign companies on domestic and cross-border mergers, acquisitions, disposals, joint ventures, alliances, and other strategic operations. His practice also covers general corporate law issues (e.g. corporate governance, intra-group reorganizations, and studies around foreign companies' set-up in France) including, where necessary, the coordination of multidisciplinary legal teams in different jurisdictions.

Thibault has acted for major corporate and industrial clients in a wide range of industries, such as energy, banking, health care, chemicals, and pharmaceuticals.

Recent deals on which he has been involved include Sanofi's carve-out leading to the creation of Euroapi (specialist in the development, manufacture, and marketing of active pharmaceutical ingredients), followed by its listing on Euronext Paris; the sale by the American group Calgon Carbon Corporation of its diatomite and perlite activities in Europe (including three mining and industrial assets in France and Italy) to Imerys; and the setting up of joint ventures between Orano and the Chinese group XTC New Energy dedicated to the production of critical materials for electric vehicle batteries (with a view to setting up two production plants on an industrial site in Dunkirk).

In addition, Thibault regularly represents Sanofi in the sale of portfolios of health care and pharmaceutical products.

Experience

  • Calgon Carbon sells European diatomite and perlite business to ImerysJones Day advised Calgon Carbon Corporation in the sale of its European diatomite and perlite business to Imerys.
  • Orano and XTC New Energy create two JVs dedicated to production of batteries for electric vehiclesJones Day advised Orano in the context of the setting-up of two joint-ventures dedicated to the production of critical materials for batteries for electric vehicles, together with Chinese group XTC New Energy.
  • Sanofi sells portfolio of well-established consumer healthcare brands to STADAJones Day advised Sanofi in the sale of a portfolio of 7 well-established consumer healthcare brands across several countries, including Belgium, Germany, Hungary, Spain, the U.K., as well as Nordic countries, to STADA Arzneimittel AG.
  • Sanofi sells customer healthcare products to ZentivaJones Day advised Sanofi in the sale of a portfolio of 12 customer healthcare products marketed in Europe to Zentiva K.S, a multinational pharmaceutical company headquartered in Prague, Czech Republic.
  • Sanofi sells portfolio of customer healthcare products to Phoenix LabsJones Day advised Sanofi in the sale of a portfolio of 5 customer healthcare products marketed in the United Kingdom and Ireland to Phoenix Labs, a privately-owned pharmaceutical group headquartered in Dublin, Ireland.
  • Sanofi announces carve-out creating EUROAPI and spin-off of approximately 58% of shares to its shareholdersJones Day advised Sanofi in the carve out creating EUROAPI (a leading European company dedicated to the development, production and marketing of active pharmaceutical ingredients) and the listing of this entity on Euronext Paris and the placement of 12% to the French State (through French Tech Souveraineté) for a price of up to €150 million.
  • Hilti Group acquires Fieldwire for approximately $300 millionJones Day advised the Hilti Group in its acquisition of Fieldwire, a San Francisco, California, based construction technology company specialized in construction project management software, for approximately $300 million.
    • View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.